Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Fragile X Syndrome
NCT03722290Phase 2Completed
- Sponsor
- Université de Sherbrooke
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in Fragile X syndrome (FXS), sponsored by Université de Sherbrooke. Started Sep 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03722290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722290.